Empagliflozin / Metformin Extended-Release not checked

Humanis Saglık Anonim Sirketi

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“1 extended Release tablet of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet”In the company’s words, NCT07694115 on ClinicalTrials.gov
Tested for
Type 2 Diabetes Mellitus (T2DM)
Main trialPhase 1
“An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets 25mg/1000mg in healthy subject in fasting condition.”In the company’s words, NCT07694115 on ClinicalTrials.gov
Copy of
Synjardy XR (Boehringer Ingelheim)Tested side by side with the original in NCT07694115

Other drugs for Type 2 Diabetes Mellitus (T2DM)

All 128 drugs for Type 2 Diabetes Mellitus (T2DM)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 29 Jun 2026 Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Empagliflozin / Metformin Extended-Release

Following is part of Solo: you see every change to Empagliflozin / Metformin Extended-Release the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in